Q2 2023

Filed Aug 14, 2023 · 10-Q · 45 days after period end · 0001493152-23-028545

Q2 2023 · 10-Q

Revenue—

Net Income

-$589.09K

N/M vs Q2 2022

EPS Diluted

$0.00

— vs Q2 2022

Operating Income-$480,676N/M

Operating Cash Flowderived-$272,590N/M

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	—	—	$0.00	$0.00
Net Income	-$589.09K	-$1.04M	-$2.75M	-$568.80K
EPS Diluted	$0.00	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Kraig Biocraft Laboratories, Inc. · CIK 1413119 · Engraved from SEC EDGAR